TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00863174
Drug: Reference147709
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference147709 injection
Study: NCT01824693
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04958720
Drug: Chemotherapy, anti-targeted agents and immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy, anti-targeted agents and immunotherapy
Study: NCT01746940
Drug: Placebo Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Topical Solution
Study: NCT02700919
Drug: BCT197
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules will be taken orally with fluids over a 5 day period after randomization
Study: NCT02700919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules will be taken orally with fluids over a 5 day period after randomization
Study: NCT00240487
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive inhaled Nitric Oxide at a dose of 10 parts per million (ppm) for a 4 hour study period. Blood gases will be collected once an hour.
Study: NCT04120233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo administered orally
Study: NCT04120233
Drug: MW151, 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg MW151, 1 x 10mg capsule administered orally
Study: NCT04120233
Drug: MW151, 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg MW151, 1 x 20mg capsule administered orally
Study: NCT04120233
Drug: MW151, 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg MW151, 2 x 20mg capsule administered orally
Study: NCT04120233
Drug: MW151, 80mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg MW151, 1 x 80mg capsule administered orally
Study: NCT04120233
Drug: MW151, 160mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg MW151, 2 x 80mg capsule administered orally
Study: NCT00452244
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40mg/QD po daily every 3 weeks
Study: NCT01258608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution for intravenous infusion will be administered as placebo for mapatumumab
Study: NCT04205630
Drug: SYD985
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYD985 powder for concentrate for solution for infusion
Study: NCT00587327
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution for IV administration. Bolus and infusion for 4 hours.
Study: NCT01297309
Drug: NPSP558
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will inject NPSP558 individual titration of 25, 50, 75 or 100 μg SC QD into alternating thighs in the morning via a multidose injection pen device.
Study: NCT00879138
Drug: VA106483
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00024193
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00024193
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04088110
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
Study: NCT01364389
Drug: AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg
Study: NCT01364389
Drug: ACZ885
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg
Study: NCT01364389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to AIN457, ACZ885 and prednisone
Study: NCT05671315
Drug: Nucleos(t)ide analogue
Normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAs: Dose please follow the approved dosage, once daily, from the first day until when discontinuation is indicated.~NAs Discontinuation Criteria: A total course of treatment is recommended for at least 4 years, and discontinuation may be considered if HBV DNA is below the lower limit of detection, Alanine aminotransferase renormalization, and HBeAg serological conversion, and remain unchanged (test every 6 months) during a consolidation therapy for at least 3 years. However, a prolonged course of treatment may reduce relapse.
Study: NCT01967472
Drug: Artemether-lumefantrine combination (AL) dispersable
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00334646
Drug: Oral GW679769
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150mg oral, once daily on days 1-3
Study: NCT00334646
Drug: IV Cyclophosphamide 500-700mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Cyclophosphamide 500-700mg/m2 on day 1 of each cycle
Study: NCT03223350
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo cream
Study: NCT03402295
Drug: Bortezomib, cyclophosphamide, thalidomide, dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between two triple combination chemotherapy that include in different new drugs (bortezomibe e talidomida)
Study: NCT02983019
Drug: Kagocel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigators could prescribe other drugs in frame of routine clinical practice
Study: NCT01171391
Drug: VA106483
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
Study: NCT05759416
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo intra-pocket application
Study: NCT03709355
Drug: Elpida®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elpida® capsules, 20mg
Study: NCT03709355
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin Film-coated tablets, 250mg
Study: NCT03709355
Drug: Levonorgestrel+Ethinylestradiol
Normalized name: levonorgestrel and ethinylestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 150 μg + Ethinylestradiol 30 μg, Film-coated tablets
Study: NCT02889757
Drug: Acteylcysteine
Normalized name: Acetylcysteine
DrugBank: Acetylcysteine magnesium (DB14080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: randomized into three arms
Study: NCT02514629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02514629
Drug: Metformin + Testosterone Undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02181803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD
Study: NCT02181803
Drug: Base Monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone \[not to exceed daily dose of 6 mg\], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.
Study: NCT03824379
Drug: Antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: insulin or oral hypoglycemics
Study: NCT03065868
Drug: H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication (Triple Therapy) as first line treatment if eradication failure, quadruple therpy will be provided as 2nd line treatment
Study: NCT01180855
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill nightly for 42 nights.
Study: NCT03188848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose subcutaneous injection of placebo to match BPI-3016
Study: NCT00950066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of a placebo once a day
Study: NCT01253187
Drug: EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group A: Single 1 film-coated tablet (Ethinylestradiol \[EE\] 0.02mg / Drospirenone \[DRSP\] 3mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
Study: NCT01253187
Drug: EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group B: Single 1 film-coated tablet (Ethinylestradiol \[EE\] 0.02mg / Drospirenone \[DRSP\] 3mg / L-5-methyltetrahydrofolate \[L-5-MTHF\] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
Study: NCT01421433
Drug: Tandrilax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandrilax (caffeine, carisoprodol, sodium diclofenac, paracetamol). Tablets, administered 3 times a day, for 7 consecutive days.
Study: NCT01253187
Drug: L-5-MTHF 0.451mg (Metafolin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group C: Single 1 coated tablet (L-5-methyltetrahydrofolate \[L-5-MTHF\] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
Study: NCT01421433
Drug: Dolamin Flex
Normalized name: Ed Flex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolamin Flex (lysine clonixinate and cyclobenzaprine). Tablets, administered 3 times a day, for 7 consecutive days.
Study: NCT03561090
Drug: IW-3718
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT03561090
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT01268033
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two infusions - at the dose of 375 mg/m² - will be administrered at one week of interval
Study: NCT03561090
Drug: Standard-dose PPIs QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: background therapy
Study: NCT04499573
Drug: CD19/CD22 CAR-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment plan will be based on stratification by the initial leukemia burden.~Patients with low disease burden will receive a lymphodepletion chemotherapy of fludarabine (total dose 120mg/m2) and cyclophosphamide (total dose 750mg/m2) over 5 days.~Patients will high disease burden will receive a lymphodepletion chemotherapy of fludarabine (total dose 120 mg/m2), cyclophosphamide (total dose 750 mg/m2), cytarabine (total dose 900 mg/m2), etoposide (total dose 450 mg/m2), dexamethasone (total dose 30 mg/m2) over 5 days.~Based on interim analysis the following dosing approach will be implemented starting April 2021:~Cohort 1: CD19+ disease, low and high burden: 1st dose - 150k/kg, 2nd dose - 850k/kg Cohort 2: CD19- disease, low and high burden: 1st dose - 500k/kg, 2nd dose - 500k/kg Cohort 3: HSCT+CAR-T: 100k/kg
Study: NCT02163733
Drug: AZD9291 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
Study: NCT03789682
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: adjuvant chemotherapy using Gemcitabine plus Cisplatin
Study: NCT05649761
Drug: QL1604 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive QL1604 injection 0.3 mg/kg,1mg/kg, 3mg/kg,10mg/kg, or 200mg intravenous every 2 weeks or every 3 weeks and will be continued until disease progression or unacceptable toxicity.
Study: NCT01506505
Drug: Cardiovascular Agents
Normalized name: CARDIOVASCULAR AGENTS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg in individual agents or a combination pill
Study: NCT04043923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT05914896
Drug: HighOsmo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group received a priming solution with high osmolality
Study: NCT02884297
Drug: Contrast agent: SonoVue®.
Approvals — FDA: no, EMA: no, PMDA: no
Description: SonoVue® Injection: will be done through the peripheral venous way already set up by the anesthetist for its injection. None venous dedicated way will be established. The injection will take place when the woman will be under general anesthesia, ventilated and under constant cardio-respiratory monitoring.
Study: NCT00253968
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT00004831
Drug: cysteine hydrochloride
Normalized name: Cysteine Hydrochloride
DrugBank: Cysteine (DB00151)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02414269
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive cyclophosphamide intravenously (at 1.5 g/m\^2)
Study: NCT04233476
Drug: 99mTc-3PRGD2 injection
Normalized name: Technetium (99mTc), particles for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: A diagnostic drug targeting integrin αvβ3, technetium-99m \[99mTc\] labeled hydrazinonicotinamide-PEG4-E\[PEG4-c(RGDfk)\]2 (99mTc-3PRGD2), will be intravenously injected to the participants for imaging of lung cancer and mapping lymph node metastasis via single photon emission computed tomography/ X-ray computed tomography (SPECT/CT) .
Study: NCT01845740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously once weekly for 4 weeks.
Study: NCT02639260
Drug: N-acetyl D-mannosamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose escalation
Study: NCT00728936
Drug: IMO-2125
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system
Study: NCT00728936
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline placebo given subcutaneously
Study: NCT00430794
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03493191
Drug: 0.5μg/kg SHR0410
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose of 0.5μg/kg SHR0410
Study: NCT03493191
Drug: 1μg/kg SHR0410
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose of 2μg/kg SHR0410
Study: NCT03493191
Drug: 2μg/kg SHR0410
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose of 2μg/kg SHR0410
Study: NCT03493191
Drug: 5μg/kg SHR0410
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose of 5μg/kg SHR0410
Study: NCT03493191
Drug: 10μg/kg SHR0410
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose of 10μg/kg SHR0410
Study: NCT03493191
Drug: 20μg/kg SHR0410
Approvals — FDA: no, EMA: no, PMDA: no
Description: a single dose of 20μg/kg SHR0410
Study: NCT01334229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 6 weeks
Study: NCT02911818
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01943188
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02934152
Drug: H pylori eradication
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: H pylori eradication
Study: NCT03498092
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline in a volume of 0.5 ml/kg
Study: NCT02320240
Drug: Desvenlafaxine
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current exposure to Desvenlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
Study: NCT01734759
Drug: Taste Test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested.~Medications to be sampled and the corresponding dose of the test dose are:~* Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg~* Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg~* Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg~* Steroids: prednisolone 1.5 mg, prednisone 0.5 mg~* H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg
Study: NCT02320240
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Current exposure to Fluoxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
Study: NCT04404712
Drug: [11C]MK-3168
Approvals — FDA: no, EMA: no, PMDA: no
Description: One PET scan involving administration of PET ligand \[11C\]MK-3168
Study: NCT02308748
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (#2 Gelcap or IV saline)
Study: NCT03588026
Drug: rVA576
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of treatment, rVA576 plus SOC. Followed by a further 3 months of rVA576 plus SOC. In total, 9 months on rVA576 plus SOC.
Study: NCT00558311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered by continuous infusion matching clazosentan administration
Study: NCT01346748
Drug: statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinvastatin 80 mg per day - 21 days versus placebo
Study: NCT00003532
Drug: Antineoplaston therapy (Atengenal + Astugenal)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with Stage III or IV Ovarian Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT02429765
Drug: ACL/FOR
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01489995
Drug: A (migalastat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg migalastat HCl in the fasting state (reference arm)
Study: NCT01489995
Drug: B (migalastat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg migalastat HCl with simultaneous consumption of a glucose drink
Study: NCT01489995
Drug: E (migalastat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg migalastat HCl 1 hour after consumption of a light meal
Study: NCT04270214
Drug: Dysport Injectable Product
Normalized name: Dysport Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dysport injections optimized using kinematics
Study: NCT01800968
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02136641
Drug: Midazolam+Fentanyl Combination
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Was applied Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, IV (in the vein), single dose.
Study: NCT01215292
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 gm of 1% T Gel applied transdermally for 10 days
Study: NCT00403416
Drug: AEB071
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00403416
Drug: Mycophenolic Acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02251990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet matching grazoprevir/elbasvir FDC tablet taken q.d. by mouth for 12 weeks.
Study: NCT00570063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days.
Study: NCT01395381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo given once
Study: NCT00274638
Drug: Telmisartan & Hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04169308
Drug: Restylane-L® Filler injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restylane-L® Filler injection into the soft tissue of the nose
Study: NCT00540124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once a day
Study: NCT02763800
Drug: BIA 3-202
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 3-202 (50, 100 and 200 mg) was administered in the form of oral tablets, given with 200 ml potable water.
Study: NCT02763800
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo was administered in the form of oral tablets, given with 200 ml potable water
Study: NCT02451527
Drug: PEX168
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEX168 in subcutaneous injection on Day8，15，22，29 and Day 36
Study: NCT01939548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo BID until the Week 12 visit
Study: NCT00700921
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg po once daily
Study: NCT00700921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule, once daily
Study: NCT03493048
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: leucovorin 200 mg/m²
Study: NCT04204629
Drug: HIP1601 40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dosing of HIP1601 40mg, PO
Study: NCT00293150
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00877006
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00877006
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01773070
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug is not administered -- this study is follow-up for participants previously receiving the drug.
Study: NCT01773070
Drug: ABT-267
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug is not administered -- this study is follow-up for participants previously receiving the drug.
Study: NCT01993225
Drug: Androxal 12.5 mg/25 mg
Approvals — FDA: no, EMA: no, PMDA: no